Altimmune, Inc. (NASDAQ:ALT – Get Free Report) CEO Jerome Durso bought 30,700 shares of the stock in a transaction dated Friday, November 13th. The stock was bought at an average cost of $1.62 per share, with a total value of $49,734.00. Following the purchase, the chief executive officer owned 93,200 shares in the company, valued at $150,984. The trade was a 49.12% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Altimmune Stock Performance
NASDAQ:ALT opened at $1.65 on Monday. The company has a fifty day moving average of $2.58 and a 200 day moving average of $3.15. Altimmune, Inc. has a 52 week low of $1.58 and a 52 week high of $6.44. The company has a quick ratio of 23.93, a current ratio of 23.93 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $319.98 million, a P/E ratio of -2.28 and a beta of 0.16.
Altimmune (NASDAQ:ALT – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). On average, research analysts predict that Altimmune, Inc. will post -0.58 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of ALT. Parallel Advisors LLC raised its stake in Altimmune by 21,755.0% during the 3rd quarter. Parallel Advisors LLC now owns 8,742 shares of the company’s stock valued at $25,000 after buying an additional 8,702 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Altimmune during the 3rd quarter valued at about $28,000. IPG Investment Advisors LLC bought a new position in shares of Altimmune in the 3rd quarter worth approximately $29,000. Quantinno Capital Management LP purchased a new position in shares of Altimmune in the first quarter worth approximately $33,000. Finally, B. Riley Wealth Advisors Inc. bought a new stake in Altimmune during the third quarter valued at approximately $36,000. 78.05% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on ALT. Weiss Ratings downgraded Altimmune from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research report on Friday. HC Wainwright restated a “buy” rating on shares of Altimmune in a report on Tuesday, July 28th. B. Riley Financial reiterated a “buy” rating on shares of Altimmune in a report on Friday. Finally, Wall Street Zen downgraded Altimmune from a “sell” rating to a “strong sell” rating in a research note on Saturday. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.33.
Trending Headlines about Altimmune
Here are a few of the latest headlines about ALT:
- Positive Sentiment: CEO Jerome Durso, CFO Gregory Weaver, and director Wayne Pisano reported open-market purchases totaling 50,700 shares at prices of $1.62–$1.64. The buys increased each executive’s or director’s holdings and may signal confidence in the company. CEO filing CFO filing Director filing
- Neutral Sentiment: B. Riley reaffirmed its Buy rating, providing supportive analyst sentiment, although the rating is not a guarantee of future performance.
- Negative Sentiment: A Seeking Alpha analysis characterized pemvidutide’s development as late and capital-intensive, underscoring the risk that lengthy trials and spending could weigh on ALT before any potential product revenue. Analysis
About Altimmune
Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.
Recommended Stories
- Five stocks we like better than Altimmune
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.
